Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group

NCT00836654 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT00836654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group
Lead sponsor
Neovii Biotech
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2004
Completion date
November 30, 2006
Enrollment
258 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epcam positive tumor (e.g.ovarian, gastric, colon, breast), malignant ascites